Skip to main content
Top
Published in: Acta Diabetologica 4/2013

01-08-2013 | Original Article

Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy

Authors: Ahmed M. Abu El-Asrar, Mohd Imtiaz Nawaz, Dustan Kangave, Mohammed Miraj Siddiquei, Mohammad Shamsul Ola, Ghislain Opdenakker

Published in: Acta Diabetologica | Issue 4/2013

Login to get access

Abstract

We determined the levels of the endogenous angiogenesis inhibitors soluble vascular endothelial growth factor receptor-1 (sVEGFR-1), thrombospondin (TSP)-1 and TSP-2 in the vitreous fluid from patients with proliferative diabetic retinopathy (PDR) and correlated their levels with clinical disease activity and the levels of vascular endothelial growth factor (VEGF). Vitreous samples from 30 PDR and 25 nondiabetic patients were studied by enzyme-linked immunosorbent assay. TSP-1 was not detected. VEGF and TSP-2 levels were significantly higher in PDR with active neovascularization compared with inactive PDR and nondiabetic patients (P < 0.001 for both comparisons). VEGF, sVEGFR-1 and TSP-2 levels were significantly higher in PDR with hemorrhage compared with PDR without hemorrhage and nondiabetic patients (P = 0.0063; 0.0144; <0.001, respectively). VEGF and sVEGFR-1 levels were significantly higher in PDR without traction retinal detachment (TRD) compared with PDR with TRD and nondiabetic patients (P = 0.038; 0.022, respectively). TSP-2 levels were significantly higher in PDR with TRD compared with PDR without TRD and nondiabetic patients (P < 0.001). There was a significant correlation between levels of VEGF and sVEGFR-1 (r = 0.427, P = 0.038). Our findings suggest that upregulation of sVEGFR-1 and TSP-2 may be a protective mechanism against progression of angiogenesis associated with PDR. TSP-2 might be associated with TRD.
Literature
1.
go back to reference Spranger J, Pfeiffer AP (2001) New concepts in pathogenesis and treatment of diabetic retinopathy. Exp Clin Endocrinol Diabetes 109:S438–S450PubMedCrossRef Spranger J, Pfeiffer AP (2001) New concepts in pathogenesis and treatment of diabetic retinopathy. Exp Clin Endocrinol Diabetes 109:S438–S450PubMedCrossRef
2.
go back to reference Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245–248PubMedCrossRef Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245–248PubMedCrossRef
3.
go back to reference Matsunaga N, Chikaraishi Y, Izuta H, Ogata N, Shimazawa M, Matsumura M, Hara H (2008) Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology 115:1916–1922PubMedCrossRef Matsunaga N, Chikaraishi Y, Izuta H, Ogata N, Shimazawa M, Matsumura M, Hara H (2008) Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy. Ophthalmology 115:1916–1922PubMedCrossRef
4.
go back to reference Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469–478PubMedCrossRef Shibuya M (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis. J Biochem Mol Biol 39:469–478PubMedCrossRef
5.
go back to reference Wu FTH, Stefanini MO, Gabhann FM, Kontos CD, Annex BH, Popel AS (2010) A system biology perspective on sVEGFR-1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 14:528–552PubMed Wu FTH, Stefanini MO, Gabhann FM, Kontos CD, Annex BH, Popel AS (2010) A system biology perspective on sVEGFR-1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med 14:528–552PubMed
6.
7.
go back to reference Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL (1994) Vascular endothelial growth factor in ocular fluid in patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMedCrossRef Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL (1994) Vascular endothelial growth factor in ocular fluid in patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487PubMedCrossRef
8.
go back to reference Rota R, Riccioni T, Zaccarini M, Lamartina S, Gallo AD, Fusco A, Kovesdi I, Balestrazzi E, Abeni DC, Ali RR, Capogrossi MC (2004) Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 6:992–1002PubMedCrossRef Rota R, Riccioni T, Zaccarini M, Lamartina S, Gallo AD, Fusco A, Kovesdi I, Balestrazzi E, Abeni DC, Ali RR, Capogrossi MC (2004) Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 6:992–1002PubMedCrossRef
9.
go back to reference Kyriakides TR, Tam JW (1999) Bornstein. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol 113:782–787PubMedCrossRef Kyriakides TR, Tam JW (1999) Bornstein. Accelerated wound healing in mice with a disruption of the thrombospondin 2 gene. J Invest Dermatol 113:782–787PubMedCrossRef
10.
go back to reference Lin T-N, Kim G-M, Chen J-J, Cheung W-M, He YY, Hsu CY (2003) Differential regulation of thrombospondin-1 and thrombospondin-2 after focal cerebral ischemia/reperfusion. Stroke 34:177–186PubMedCrossRef Lin T-N, Kim G-M, Chen J-J, Cheung W-M, He YY, Hsu CY (2003) Differential regulation of thrombospondin-1 and thrombospondin-2 after focal cerebral ischemia/reperfusion. Stroke 34:177–186PubMedCrossRef
11.
go back to reference Hawighorst T, Velasco P, Streit M, Hong Y-K, Kyriakides TR, Brown LF, Bornstein P, Detmar M (2001) Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 20:2631–2640PubMedCrossRef Hawighorst T, Velasco P, Streit M, Hong Y-K, Kyriakides TR, Brown LF, Bornstein P, Detmar M (2001) Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J 20:2631–2640PubMedCrossRef
12.
go back to reference Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, Detmar M (1999) Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 96:14888–14893PubMedCrossRef Streit M, Riccardi L, Velasco P, Brown LF, Hawighorst T, Bornstein P, Detmar M (1999) Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci USA 96:14888–14893PubMedCrossRef
13.
go back to reference Noh Y-H, Matsuda K, Hong Y-K, Kunstfeld R, Riccardi L, Koch M, Oura H, Dadras SS, Streit M, Detmar M (2003) An N-terminal 80 kDa recombinant fragment of human thrombopsondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. J Invest Dermatol 121:1536–1543PubMedCrossRef Noh Y-H, Matsuda K, Hong Y-K, Kunstfeld R, Riccardi L, Koch M, Oura H, Dadras SS, Streit M, Detmar M (2003) An N-terminal 80 kDa recombinant fragment of human thrombopsondin-2 inhibits vascular endothelial growth factor induced endothelial cell migration in vitro and tumor growth and angiogenesis in vivo. J Invest Dermatol 121:1536–1543PubMedCrossRef
14.
go back to reference Koch M, Hussein F, Woeste A, Gründker C, Frontzek K, Emons G, Hawighorst T (2011) CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Res Treat 128:337–346PubMedCrossRef Koch M, Hussein F, Woeste A, Gründker C, Frontzek K, Emons G, Hawighorst T (2011) CD36-mediated activation of endothelial cell apoptosis by an N-terminal recombinant fragment of thrombospondin-2 inhibits breast cancer growth and metastasis in vivo. Breast Cancer Res Treat 128:337–346PubMedCrossRef
15.
go back to reference MacLauchlan S, Skokos EA, Agah A, Zeng J, Tian W, Davidson JM, Bornstein P, Kyriakides TR (2009) Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and-9 and soluble VEGF. J Histochem Cytochem 57:301–313PubMedCrossRef MacLauchlan S, Skokos EA, Agah A, Zeng J, Tian W, Davidson JM, Bornstein P, Kyriakides TR (2009) Enhanced angiogenesis and reduced contraction in thrombospondin-2-null wounds is associated with increased levels of matrix metalloproteinases-2 and-9 and soluble VEGF. J Histochem Cytochem 57:301–313PubMedCrossRef
16.
go back to reference Kyriakides TR, Zhu Y-H, Yang Z, Huynh G, Bornstein P (2001) Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol 159:1255–1262PubMedCrossRef Kyriakides TR, Zhu Y-H, Yang Z, Huynh G, Bornstein P (2001) Altered extracellular matrix remodeling and angiogenesis in sponge granulomas of thrombospondin 2-null mice. Am J Pathol 159:1255–1262PubMedCrossRef
17.
go back to reference Krady MM, Zeng J, Yu J, MacLauchlan S, Skokos EA, Tian W, Bornstein P, Sessa WC, Kyriakides TR (2008) Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am J Pathol 173:879–891PubMedCrossRef Krady MM, Zeng J, Yu J, MacLauchlan S, Skokos EA, Tian W, Bornstein P, Sessa WC, Kyriakides TR (2008) Thrombospondin-2 modulates extracellular matrix remodeling during physiological angiogenesis. Am J Pathol 173:879–891PubMedCrossRef
18.
go back to reference Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM (2004) Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 165:2087–2098PubMedCrossRef Park YW, Kang YM, Butterfield J, Detmar M, Goronzy JJ, Weyand CM (2004) Thrombospondin 2 functions as an endogenous regulator of angiogenesis and inflammation in rheumatoid arthritis. Am J Pathol 165:2087–2098PubMedCrossRef
19.
go back to reference Armstrong LC, Björkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P (2002) Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 13:1893–1905PubMedCrossRef Armstrong LC, Björkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P (2002) Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell 13:1893–1905PubMedCrossRef
20.
go back to reference Simantov R, Febbraio M, Silverstein RL (2005) The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 24:27–34PubMedCrossRef Simantov R, Febbraio M, Silverstein RL (2005) The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol 24:27–34PubMedCrossRef
21.
go back to reference Adri VC, Kupriyanova TA, Deryugina EI, Quigley JP (2007) Human neutrophils uniquely release TIMP-Free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 104:20262–20267CrossRef Adri VC, Kupriyanova TA, Deryugina EI, Quigley JP (2007) Human neutrophils uniquely release TIMP-Free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc Natl Acad Sci USA 104:20262–20267CrossRef
22.
go back to reference Bergers G, Prekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Natl Cell Biol 2:737–744CrossRef Bergers G, Prekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D (2000) Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Natl Cell Biol 2:737–744CrossRef
23.
go back to reference Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681–691PubMedCrossRef Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681–691PubMedCrossRef
24.
go back to reference Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J (2006) Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw 17:155–165PubMed Abu El-Asrar AM, Struyf S, Kangave D, Geboes K, Van Damme J (2006) Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Eur Cytokine Netw 17:155–165PubMed
25.
go back to reference Ogata N, Ando A, Uyama M, Matsumura M (2001) Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells. Graefes Arch Exp Ophthalmol 239:87–95CrossRef Ogata N, Ando A, Uyama M, Matsumura M (2001) Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells. Graefes Arch Exp Ophthalmol 239:87–95CrossRef
26.
go back to reference Xiao M, McLeod D, Cranley J, Williams G, Boulton M (1999) Growth factor staining patterns in the pig retina following retinal laser photocoagulation. Br J Ophthalmol 83:728–736PubMedCrossRef Xiao M, McLeod D, Cranley J, Williams G, Boulton M (1999) Growth factor staining patterns in the pig retina following retinal laser photocoagulation. Br J Ophthalmol 83:728–736PubMedCrossRef
Metadata
Title
Angiogenesis regulatory factors in the vitreous from patients with proliferative diabetic retinopathy
Authors
Ahmed M. Abu El-Asrar
Mohd Imtiaz Nawaz
Dustan Kangave
Mohammed Miraj Siddiquei
Mohammad Shamsul Ola
Ghislain Opdenakker
Publication date
01-08-2013
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2013
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-011-0330-9

Other articles of this Issue 4/2013

Acta Diabetologica 4/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.